1 BTC
=
- USD
Incyte Genomics Inc
As of May 30, 2026 at 24:05 UTC
Chart
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Market Statistics
Trading Metrics
How to Buy INCY
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy INCY
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesCMS reported successful phase 3 clinical trial results for ruxolitinib cream in treating mild to moderate atopic dermatitis, with significantly higher patient improvement rates compared to placebo and minimal adverse events.
The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.
Merus reported positive interim data from its Phase II trial of petosemtamab in combination with pembrolizumab for first-line treatment of recurrent/metastatic HNSCC expressing PD-L1. The company also provided updates on its ongoing Phase III trials for petosemtamab and its collaboration programs.
The global generic oncology drugs market is expected to grow from $24.39 billion in 2025 to $30.99 billion by 2034, driven by rising cancer rates and demand for affordable treatments. The market is dominated by North America and is projected to see the fastest growth in Asia Pacific.
The atopic dermatitis drugs market is projected to reach $31 billion by 2034, driven by the rising prevalence of the condition, advancements in biologic therapies, and growing awareness. The biologics segment led the market in 2024, with new biologic injections targeting inflammatory pathways expanding treatment options.
